Methotrexate (high-dose)
Trexall · Antifolate
Crystal nephropathy; glucarpidase rescue.
XTALATN
ModerateOpen →
Anti-CD20 antibody
Rituximab
Rituxan · Ritux
The anti-CD20 workhorse — its rapid kill of bulky B-cell disease can ignite tumor lysis and crystal nephropathy.
ModerateAnti-CD20 antibody · approved 1997
B-cell non-Hodgkin lymphomaCLL/SLLAutoimmune/glomerular disease (e.g., membranous nephropathy, ANCA vasculitis)
Signature kidney injury
Crystal / Obstructive Nephropathy
Clinical tumor lysis with the first cycle is uncommon with modern prophylaxis (~1% clinical TLS in a real-world fractionated-rituximab aggressive-B-NHL series), but risk rises sharply with bulky disease, high LDH and Burkitt histology.
Source: Mohamad et al., Cancer Rep 2024 (~1% clinical TLS)
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityPartially reversible
Evidence0 refs
Nephron map
Vasculature / Endothelium
Proximal Tubule
Distal Tubule / Collecting Duct
Tubular LumenThe urine flow path
Crystal / Obstructive Nephropathy
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Mechanism of kidney injury
Rapid, complement- and ADCC-mediated lysis of bulky/high-burden B-cell malignancy releases potassium, phosphate and nucleic acids; uric acid (from nucleic-acid catabolism) and calcium-phosphate crystallize within distal tubules causing intratubular obstruction (crystal nephropathy), with urate-mediated afferent vasoconstriction and ischemic ATN — tumor-lysis AKI. In-vitro work shows CD20 antibodies can kill target cells within 12–24 h, accounting for the early TLS window.
Clinical presentation
Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and rising creatinine, usually within the first cycle of treatment of bulky disease. Infusion-related reactions (cytokine release) are common but not directly nephrotoxic.
Onset
Acute — typically within hours to a few days of the first infusion.
Reversibility
Partially reversible
Anticancer mechanism
Chimeric anti-CD20 IgG1 monoclonal antibody depleting B cells through complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC)/phagocytosis, and direct signaling-induced cell death; backbone of B-cell non-Hodgkin lymphoma and CLL regimens and a therapeutic in several glomerular/autoimmune diseases.
Management
IV hydration, rasburicase for hyperuricemia, correct hyperkalemia/hyperphosphatemia/hypocalcemia; renal replacement therapy for severe/refractory cases (lower threshold given ongoing lysis).
Risk factors
- Bulky disease / high tumor burden (e.g., Burkitt, high-grade B-NHL)
- Elevated baseline LDH (≥2× ULN)
- Pre-existing CKD
- Volume depletion
- High circulating tumor cell count
Prevention
- Risk-stratified TLS prophylaxis (hydration, allopurinol or rasburicase)
- Fractionated/step-up first-dose administration in high-burden disease
- Laboratory monitoring during the first cycle
- Rasburicase for high-risk patients (rapidly lowers uric acid and improves GFR)
Note · Rituximab itself is not directly tubulotoxic; the renal risk is tumor-lysis-mediated. Paradoxically, rituximab is also used therapeutically to TREAT glomerular diseases (e.g., membranous nephropathy, ANCA vasculitis) — a notable double identity in onconephrology.
Clinical depth
Renal dose adjustment
No renal dose adjustment; as a monoclonal antibody it is cleared by reticuloendothelial/target-mediated mechanisms, not the kidney, and is dosed by BSA/flat dose regardless of CrCl. Renal function changes are driven by the tumor-lysis risk it provokes, not by drug accumulation.
Dialyzability & ESKD dosing
Not dialyzed — a ~145 kDa IgG1 antibody is not removed by hemodialysis or peritoneal dialysis. No supplemental dosing around dialysis; usable in ESKD at standard doses. Dialysis is used to treat TLS metabolic complications.
Differential diagnosis
Tumor-lysis crystal nephropathy (urate/phosphate profile, early post-infusion) vs lymphomatous renal infiltration vs obstruction from bulky retroperitoneal nodes vs prerenal azotemia. When rituximab is given FOR glomerular disease, a creatinine change reflects the underlying nephropathy, not drug toxicity.
Monitoring
- TLS panel (uric acid, potassium, phosphate, calcium, creatinine) before and during the first cycle in at-risk patients
- Volume status and urine output
- Infusion-reaction monitoring (premedicate; not nephrotoxic but can cause hemodynamic instability)
Key trials & series
- Coiffier et al., JCO 2008 — foundational pediatric/adult TLS management guideline anchoring B-NHL risk stratification
- Galardy et al., Br J Haematol 2013 — Children's Oncology Group: rasburicase prevents renal failure and improves GFR in advanced B-NHL TLS
- Mohamad et al., Cancer Rep 2024 — real-world fractionated rituximab with ~1% clinical TLS
Clinical pearls
- Rituximab's nephrotoxicity is tumor-lysis-mediated — highest with bulky, high-LDH, Burkitt-type disease; prophylax accordingly.
- Fractionated first dosing and rasburicase blunt the TLS/AKI risk; clinical TLS is now ~1% in real-world aggressive B-NHL.
- Remember its dual role: rituximab also TREATS membranous nephropathy and ANCA vasculitis.
Where it strikes
Nephron segments
Tubular Lumen
The urine flow path
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Crystal / Obstructive NephropathyAcute Tubular NecrosisPrerenal / Hemodynamic AKIElectrolyte Wasting
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.Coiffier B et al. · J Clin Oncol 2008 · PMID 18509186Foundational TLS risk-stratification/prophylaxis guideline (hydration, rasburicase, renal endpoints) anchoring rituximab B-NHL context.PMIDEffectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practice.Mohamad J et al. · Cancer Rep (Hoboken) 2024 · PMID 39410860Real-world series: ~1% clinical TLS with fractionated rituximab plus prophylaxis.PMIDRasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.Galardy PJ et al. · Br J Haematol 2013 · PMID 24032600Rasburicase prevents new-onset renal failure and improves GFR in high-risk B-NHL TLS.PMIDDirect Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis.Constantinides M et al. · Cancers (Basel) 2023 · PMID 36831451Mechanism: rituximab/obinutuzumab induce rapid direct killing (<12–24 h), explaining the early TLS window.PMIDRenal involvement in chronic lymphocytic leukemia.Wanchoo R et al. · Clin Kidney J 2018 · PMID 30288263Onconephrology review including anti-CD20-associated tumor lysis nephropathy.PMIDEmergencies in Hematology: Why, When and How I Treat?Duminuco A et al. · J Clin Med 2024 · PMID 39768494Review of tumor lysis syndrome pathophysiology, electrolyte derangements and AKI management.